Amylyx Pharmaceuticals, Inc. Income Statement

Income Statement Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue 0.28M27.10M431.43M114.27M
Cost of Revenue 2.99M25.44M5.95M
Gross Profit 0.28M24.11M405.99M108.31M
Operating items
Research & Development 44.04M93.45M128.19M104.08M
Selling, General & Administrative 38.93M127.13M188.36M114.33M
Restructuring Costs 22.85M
Other Operating Expenses 2.99M25.44M160.84M
Operating Expenses 82.97M223.57M341.98M402.10M
Operating Income -82.69M-201.34M38.80M-314.73M
EBIT -82.69M-201.34M38.80M-314.73M
Non-operating items
Interest & Investment Income 0.04M4.29M16.16M13.81M
Other Non Operating Income -0.05M-0.55M-0.66M-1.21M
Non Operating Income -5.24M3.74M15.49M12.60M
Net income details
EBT -87.93M-198.70M54.30M-302.14M
Tax Provisions 0.77M5.25M-0.77M
Profit After Tax -87.93M-198.38M49.27M-301.74M
Income from Continuing Operations -87.93M-199.48M49.05M-301.37M
Consolidated Net Income -87.93M-199.48M49.05M-301.37M
Income towards Parent Company -87.93M-199.48M49.05M-301.37M
Net Income towards Common Stockholders -87.93M-199.48M49.05M-301.37M
Additional items
EPS (Basic) -0.00M-0.00M0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M0.00M-0.00M
Shares Outstanding (Weighted Average) 57.86M66.26M67.52M68.55M
Shares Outstanding (Diluted Average) 6.59M58.50M69.99M
EBITDA -82.69M-201.34M38.80M-314.73M
Tax Rate 9.67%0.25%